MyOme

Executive Summary

MyOme is a clinical whole genome analysis platform that empowers families to understand their inherited disease risks through advanced polygenic modeling. Founded in 2015 and headquartered in Menlo Park, California, the company leverages whole genome sequencing to provide a lifetime of actionable insights for personalized preventive care. As a leader in polygenic risk scoring, MyOme differentiates itself by analyzing entire genomes rather than targeted panels, enabling more comprehensive risk assessment for a wide range of conditions. The platform is designed for integration into clinical workflows, helping healthcare providers deliver tailored recommendations based on genetic predisposition. Despite being privately held and lacking disclosed financials, MyOme operates in the rapidly expanding precision genomics market, driven by increasing demand for proactive health management and falling sequencing costs. The company's focus on family-based risk communication and its whole genome approach position it to capture significant value in both clinical and direct-to-consumer segments. Key challenges include regulatory hurdles, data privacy concerns, and competition from other genomics players. MyOme's ability to secure partnerships with health systems and achieve regulatory clearances will be critical for scaling its platform and driving adoption.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for Polygenic Risk Score Test for Common Diseases60% success
• Q3 2026Strategic Partnership with Major Health System for Clinical Integration70% success
• Q2 2026Series B Funding Round to Expand Commercial Operations80% success